Prescient unveils its latest powerful platform to advance personalised targeted cancer treatments
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy...
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor...
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing...
Prescient Therapeutics (ASX: PTX) signed off the March quarter with major progress made in its Cell...
According to the World Health Organisation, cancer accounted for nearly 10 million deaths in 2020,...
Australian biotechnology company Prescient Therapeutics is enrolling up to 12 new patients for the next...
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has announced the opening of enrolment...
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke explains how the company is combatting the leading, global...
Prescient Therapeutics (PTX) has opened patient enrolments for an expanded phase 1B trial of its...
Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.